drugset / Trial / NCT01440673
Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy
Completed
150 enrolled
Gachon University Gil Medical Center
Asan Medical Center · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
* Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting. * NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited. * We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.
Timeline
- Start
- 2010-03
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | — |
| Comparator | Aprepitant | Other / unclassified | 125 mg | — |
Indications
No indication recorded.